Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats

Biomedicine and Pharmacotherapy

Volumn 62, Issue 9, 2008, Pages 598-605

  Palsamy, P ^a   Subramanian, S ^a  

^a UNIVERSITY OF MADRAS   (India)

Author keywords

Diabetes mellitus; Insulin; Nicotinamide; Resveratrol; Streptozotocin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GLICLAZIDE; GLYCOSYLATED HEMOGLOBIN; NICOTINAMIDE; PHYTOALEXIN; RESVERATROL; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG EFFICACY; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; NONHUMAN; PHYTOTHERAPY; PRIORITY JOURNAL; RAT; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; NIACINAMIDE; RATS; RATS, WISTAR; STILBENES; STREPTOZOCIN; TERPENES;

EID: 54049155669     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2008.06.037     Document Type: Article

References (68)

1. Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
2. McCarthy M.I., and Hattersley A.T. Molecular diagnostics in monogenic and multifactorial forms of type 2 diabetes. Expert Rev Mol Diagn 1 (2001) 403-412
3. Gerich J.E. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med 163 (2003) 1306-1316
4. Kecskemeti V., Bagi Z., Pacher P., Posa I., Kocsis E., and Koltai M.Z. New trends in the development of oral antidiabetic drugs. Curr Med Chem 9 (2002) 53-71
5. Schuster D.P., and Duvuuri V. Diabetes mellitus. Clin Podiatr Med Surg 19 (2002) 79-107
6. Kahn S.E., Hull R.L., and Utzschneider K.M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444 (2006) 840-846
7. Krentz A.J., and Bailey C.J. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 65 (2005) 385-411
8. Nathan D.M., Buse J.B., Davidson M.B., Heine R.J., Holman R.R., Sherwin R., et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29 (2006) 1963-1972
9. Schlyer S., and Horuk R. I want a new drug: G-protein-coupled receptors in drug development. Drug Discov Today 11 (2006) 481-493
10. Witters L.A. The blooming of the French lilac. J Clin Invest 108 (2001) 1105-1107
11. Bavaresco L. Role of viticultural factors on stilbene concentrations of grapes and wine. Drugs Exp Clin Res 29 (2003) 181-187
12. Soleas G.J., Diamandis E.P., and Goldberg D.M. Resveratrol: a molecule whose time has come? And gone?. Clin Biochem 30 (1997) 91-113
13. Stewart J.R., Artime M.C., and O'Brian C.A. Resveratrol: a candidate nutritional substance for prostate cancer prevention. J Nutr 133 (2003) 2440S-2443S
14. Siemann E.H., and Creasy L.L. Concentration of the phytoalexin resveratrol in wine. Am J Enol Vitic 43 (1992) 49-52
15. Juan M.E., Vinardell M.P., and Planas J.M. The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J Nutr 132 (2002) 257-260
16. Renaud S., and de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339 (1992) 1523-1526
17. Joe A.K., Liu H., Suzui M., Vural M.E., Xiao D., and Weinstein I.B. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res 8 (2002) 893-903
18. Bhat K.P.L., Kosmeder II J.W., and Pezzuto J.M. Biological effects of resveratrol. Antioxid Redox Signal 3 (2001) 1041-1064
19. Virgili M., and Contestabile A. Partial neuroprotection of in vivo excitotoxic brain damage by chronic administration of the red wine antioxidant agent, trans-resveratrol in rats. Neurosci Lett 281 (2000) 123-126
20. Gao X., Xu Y.X., Divine G., Janakiraman N., Chapman R.A., and Gautam S.C. Disparate in vitro and in vivo antileukemic effects of resveratrol, a natural polyphenolic compound found in grapes. J Nutr 132 (2002) 2076-2081
21. Das D.K., Sato M., Ray P.S., Maulik G., Engelman R.M., Bertelli A.A., et al. Cardioprotection of red wine: role of polyphenolic antioxidants. Drugs Exp Clin Res 25 (1999) 115-120
22. Frankel E.N., Waterhouse A.L., and Kinsella J.E. Inhibition of human LDL oxidation by resveratrol. Lancet 341 (1993) 1103-1104
23. Pace-Asciak C.R., Hahn S., Diamandis E.P., Soleas G., and Goldberg D.M. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 235 (1995) 207-219
24. Fontecave M., Lepoivre M., Elleingand E., Gerez C., and Guittet O. Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett 421 (1998) 277-279
25. Chun Y.J., Kim M.Y., and Guengerich F.P. Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem Biophys Res Commun 262 (1999) 20-24
26. Rakieten N., Rakieten M.L., and Nadkarni M.R. Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother Rep 29 (1963) 91-98
27. Masiello P., Broca C., Gross R., Roye M., Manteghetti M., Hillaire-Buys D., et al. Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide. Diabetes 47 (1998) 224-229
28. Pulido N., Suarez A., Casanova B., Romero R., Rodriguez E., and Rovira A. Gliclazide treatment of streptozotocin diabetic rats restores GLUT4 protein content and basal glucose uptake in skeletal muscle. Metabolism 46 (1997) 10-13
29. Sasaki T., Matsy S., and Sonae A. Effect of acetic acid concentration on the colour reaction in the O-toluidine boric acid method for blood glucose estimation. Rinsh Kagaku 1 (1972) 346-353
30. Drabkin D.L., and Austin J.H. Spectrophotometric constants for common hemoglobin derivatives in human, dog and rabbit blood. J Biol Chem 98 (1932) 719-733
31. Nayak S.S., and Pattabiraman T.N. A new colorimetric method for the estimation of glycosylated hemoglobin. Clin Chim Acta 109 (1981) 267-274
32. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 193 (1951) 265-275
33. Natelson S., Scott M.L., and Beffa C. A rapid method for the estimation of urea in biologic fluids. Am J Clin Pathol 21 (1951) 275-281
34. Brod J., and Sirota J.H. The renal clearance of endogenous "creatinine" in man. J Clin Invest 27 (1948) 645-654
35. Caraway W.I. Uric acid. In: Seligson D. (Ed). Standard methods of clinical chemistry, Vol. 4 (1963), Academic Press, New York 239-247
36. King J. The transaminases: alanine and aspartate transaminases. Practical clinical enzymology (1965), Van Nostrand Reinhold Co., London p. 363-95
37. King J. The hydorlases-acid and alkaline phosphatases. Practical clinical enzymology (1965), Van Nostrand Reinhold Co, London p. 199-208
38. Thulesen J., Orskov C., Holst J.J., and Poulsen S.S. Short-term insulin treatment prevents the diabetogenic action of streptozotocin in rats. Endocrinology 138 (1997) 62-68
39. Virág L., and Szabó C. The therapeutic potential of poly (ADP-ribose) polymerase inhibitors. Pharmacol Rev 54 (2002) 375-429
40. Yang H., and Wright Jr. J.R. Human beta cells are exceedingly resistant to streptozotocin in vivo. Endocrinology 143 (2002) 2491-2495
41. Shima K., Zhu M., and Kuwajima M. A role of nicotinamide-induced increase in pancreatic beta-cell mass on blood glucose control after discontinuation of the treatment in partially pancreatectomized OLETF rats. Diabetes Res Clin Pract 41 (1998) 1-8
42. Rodríguez T., Alvarez B., Busquets S., Carbó N., López-Soriano F.J., and Argilés J.M. The increased skeletal muscle protein turnover of the streptozotocin diabetic rat is associated with high concentrations of branched-chain amino acids. Biochem Mol Med 61 (1997) 87-94
43. Pepato M.T., Migliorini R.H., Goldberg A.L., and Kettelhut I.C. Role of different proteolytic pathways in degradation of muscle protein from streptozotocin-diabetic rats. Am J Physiol 271 (1996) E340-E347
44. Brodsky I.G. Nutritional effects of dietary protein restriction in insulin-dependent diabetes mellitus. J Nutr 128 (1998) 337S-339S
45. Giugliano D., Ceriello A., and Esposito K. Glucose metabolism and hyperglycemia. Am J Clin Nutr 87 (2008) 217S-222S
46. Yabe-Nishimura C. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol Rev 50 (1998) 21-33
47. Goldstein D.E., Little R.R., Lorenz R.A., Malone J.I., Nathan D.M., and Peterson C.M. Tests of glycemia in diabetes. Diabetes Care 27 (2004) S91-S93
48. Howlett J., and Ashwell M. Glycemic response and health: summary of a workshop. Am J Clin Nutr 87 (2008) 212S-216S
49. Huebschmann A.G., Regensteiner J.G., Vlassara H., and Reusch J.E. Diabetes and advanced glycoxidation end products. Diabetes Care 29 (2006) 1420-1432
50. Singleton J.R., Smith A.G., Russell J.W., and Feldman E.L. Microvascular complications of impaired glucose tolerance. Diabetes 52 (2003) 2867-2873
51. Robertson R.P. Estimation of beta-cell mass by metabolic tests: necessary, but how sufficient?. Diabetes 56 (2007) 2420-2424
52. Tominaga M., Eguchi H., Manaka H., Igarashi K., Kato T., and Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22 (1999) 920-924
53. Kilpatrick E.S. Glycated haemoglobin in the year 2000. J Clin Pathol 53 (2000) 335-339
54. Møller N., and Nair K.S. Diabetes and protein metabolism. Diabetes 57 (2008) 3-4
55. Sugden P.H., and Fuller S.J. Regulation of protein turnover in skeletal and cardiac muscle. Biochem J 273 (1991) 21-37
56. Green M., and Miller L.L. Protein catabolism and protein synthesis in perfused livers of normal and alloxan-diabetic rats. J Biol Chem 235 (1960) 3202-3208
57. Almdal T.P., Petersen K.F., Hansen B.A., and Vilstrup H. Increased capacity of urea synthesis in streptozotocin diabetes in rats. Diabetologia 29 (1986) 812-816
58. Facchini F., Chen Y.D., Hollenbeck C.B., and Reaven G.M. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 266 (1991) 3008-3011
59. Modan M., Halkin H., Karasik A., and Lusky A. Elevated serum uric acid-a facet of hyperinsulinaemia. Diabetologia 30 (1987) 713-718
60. Baynes J.W. Role of oxidative stress in development of complications in diabetes. Diabetes 40 (1991) 405-412
61. Becker B.F. Towards the physiological function of uric acid. Free Radic Biol Med 14 (1993) 615-631
62. Travlos G.S., Morris R.W., Elwell M.R., Duke A., Rosenblum S., and Thompson M.B. Frequency and relationships of clinical chemistry and liver and kidney histopathology findings in 13-week toxicity studies in rats. Toxicology 107 (1996) 17-29
63. Leclercq I.A., Da Silva Morais A., Schroyen B., Van Hul N., and Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol 47 (2007) 142-156
64. Neuschwander-Tetri B.A., and Caldwell S.H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37 (2003) 1202-1219
65. Elizabeth H., and Harris M.D. Elevated liver function tests in type 2 diabetes. Clin Diabetes 23 (2005) 115-119
66. O'Brien R.M., and Granner D.K. Regulation of gene expression by insulin. Biochem J 278 (1991) 609-619
67. Grove J., Daly A.K., Bassendine M.F., and Day C.P. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 26 (1997) 143-146
68. El-Demerdash F.M., Yousef M.I., and El-Naga N.I. Biochemical study on the hypoglycemic effects of onion and garlic in alloxan-induced diabetic rats. Food Chem Toxicol 43 (2005) 57-63